Table 1.

Comparisons in clinical and pathological characteristics of ESR1-CCDC170 fusion-positive and negative BRCA patients and control cohorts. The clinical and pathological characteristics between ESR1-CCDC170 fusion-positive, negative BRCA, and control cohorts were compared.

	Total (n = 1095)	Control (n = 48)	Fusion (n = 11)	p-Values
age	46–72	44–68	49–71	0.001
sex
- female	1082 (98.8%)	48 (100.0%)	11 (100.0%)
Vital status				1
- alive	991 (90.5%)	42 (87.5%)	10 (90.9%)
- dead	104 (9.5%)	6 (13.6%)	1 (9.1%)
stage				NS
- stage I	90 (8.3%)	2 (4.2%)	1 (9.1%)
- stage Ia	85 (7.8%)	3 (6.2%)	1 (9.1%)
- stage Ib	6 (0.6%)	0 (0.0%)	0 (0.0%)
- stage II	6 (0.6%)	0 (0.0%)	0 (0.0%)
- stage IIa	359 (33.0%)	24 (50.0%)	3 (27.3%)
- stage IIb	257 (23.6%)	9 (18.8%)	3 (27.3%)
- stage III	2 (0.2%)	0 (0.0%)	0 (0.0%)
- stage IIIa	156 (14.4%)	4 (8.3%)	2 (18.2%)
- stage IIIb	27 (2.5%)	0 (0.0%)	0 (0.0%)
- stage IIIc	65 (6.0%)	3 (6.2%)	1 (9.1%)
- stage Iv	20 (1.8%)	2 (4.2%)	0 (0.0%)
- stage x	14 (1.3%)	1 (2.1%)	0 (0.0%)
ER status				0
- positive	808 (77.2%)	10 (20.8%)	10 (90.9%)
- negative	237 (22.5%)	38 (79.2%)	0 (0.0%)
- indeterminate	2 (0.2%)	0 (0.0%)	1 (9.1%)
PR status				0
- positive	700 (66.9%)	2 (4.3%)	7 (63.6%)
- negative	342 (32.7%)	45 (95.7%)	4 (36.4%)
- indeterminate	4 (0.4%)	0 (0.0%)	0 (0.0%)
HER2 IHC				0
0	61 (9.8%)	7 (21.9%)	0 (0.0%)
- 1+	270 (43.4%)	12 (37.5%)	4 (44.4%)
- 2+	199 (32.1%)	10 (31.2%)	1 (11.1%)
- 3+	90 (14.5%)	3 (9.4%)	4 (44.4%)
subtype				0
- Basal	190 (18.0%)	42 (89.4%)	0 (0.0%)
- Her2	82 (7.8%)	5 (10.6%)	1 (9.1%)
- LumA	566 (53.6%)	0 (0.0%)	5 (45.5%)
- LumB	217 (20.6%)	0 (0.0%)	5 (45.5%)
PIK3CA mutation	301 (31.2%)	3 (6.8%)	1 (10.0%)	NS
CDH1 mutation	96 (10.0%)	0 (0.0%)	1 (10.0%)	NS
TP53 mutation	264 (27.4%)	29 (65.9%)	3 (30.0%)	NS
BRCA1 mutation	11 (1.1%)	0 (0.0%)	0 (0.0%)	NS
BRCA2 mutation	12 (1.2%)	1 (2.7%)	1 (10.0%)	NS